In vitro activity of gemifloxacin against clinical isolates of Neisseria gonorrhoeae with and without mutations in the gyrA gene

International Journal of Antimicrobial Agents

Volumn 22, Issue 1, 2003, Pages 73-76

  Ruiz, Joaquim ^a   Marco, Francesc ^a   Sierra, Josep M ^a   Aguilar, Lorenzo ^b   Garcia Mendez, Elena ^b   Mensa, Josep ^a   Jiménez De Anta, M Teresa ^a   Vila, Jordi ^a  

^a HOSPITAL CLÍNIC   (Spain)

^b Glaxo SmithKline Pharmaceuticals   (Spain)

Author keywords

Gemifloxacin; gyrA; N. gonorrhoeae; parC; Quinolones

Indexed keywords

BACTERIAL PROTEIN; CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; GEMIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; NALIDIXIC ACID; PROTEIN PARC; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TROVAFLOXACIN; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONTROLLED STUDY; GENE MUTATION; IN VITRO STUDY; MICROANGIOPATHY; MINIMUM INHIBITORY CONCENTRATION; NEISSERIA GONORRHOEAE; NONHUMAN; PRIORITY JOURNAL;

EID: 0038385201     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(03)00083-9     Document Type: Article

References (17)

1. Echols R.M., Heyd A., O'Keeffe B.J., Schacht P. Single-dose ciprofloxacin for the treatment of uncomplicated gonorrhea: a worldwide summary. Sex. Transm. Dis. 21:1994;345-352.
2. Deguchi T., Yasuda M., Nakano M., et al. Quinolone-resistant Neisseria gonorrhoeae: correlation of alterations in GyrA subunit of DNA-gyrase and the ParC subunit of topoisomerase IV with antimicrobial susceptibility profiles. Antimicrob. Agents Chemother. 40:1996;1020-1023.
3. Ison C.A., Woodford P.J., Madders H., Claydon E. Drift in susceptibility of Neisseria gonorrhoeae to ciprofloxacin and emergence of therapeutic failure. Antimicrob. Agents Chemother. 42:1998;2919-2922.
4. Vila J., Olmos L., Ballesteros J., et al. Development of in-vivo resistance after quinolone treatment of gonococcal urethritis. J. Antimicrob. Chemother. 39:1997;841.
5. Vila J., Ruiz J., Navia M.M. Molecular basis of quinolone resistance acquisition in Gram-negative bacteria. Rec. Res. Dev. Antimicrob. Agents Chemother. 3:1999;323-344.
6. Stein D.C., Danaher R.J., Cook M.T. Characterization of a gyrB mutation responsible for low-level nalidixic acid resistance in Neisseria gonorrhoeae. Antimicrob. Agents Chemother. 35:1991;622-626.
7. Berron S., Vazquez J.A., Gimenez M.J., De La Fuente L., Aguilar L. In vitro susceptibilities of 400 Spanish isolates of Neisseria gonorrhoeae to gemifloxacin and 11 other antimicrobial agents. Antimicrob. Agents Chemother. 44:2000;2543-2544.
8. Wise R., Andrews J.M. The in-vitro activity and tentative breakpoint of gemifloxacin, a new fluoroquinolone. J. Antimicrob. Chemother. 44:1999;679-686.
9. Ruiz J., Jurado A., Garcia-Méndez E., et al. Frequency of selection of fluoroquinolone-resistant mutants of Neisseria gonorrhoeae exposed to gemifloxacin and four other quinolones. J. Antimicrob. Chemother. 48:2001;545-548.
10. Lowe M.N., Lamb H.M. Gemifloxacin. Drugs. 59:2000;1137-1148.
11. National Committee for Clinical Laboratory Standards (NCCLS). Methods for dilution antimicrobial susceptibility tests for bacterial that grow aerobically. Approved Standard M7-A5. Wayne, PA, 2000.
12. Barry A.L., Fuchs P.C., Allen S.D., et al. Tentative criteria for confirming the in vitro susceptibility of Haemophilus influenzae and Neisseria gonorrhoeae to two fluoroquinolones (sparfloxacin and levofloxacin), including quality control parameters. J. Clin. Microbiol. 31:1993;2375-2380.
13. Gill M.J., Simjee S., Al-Hattawi K., Robertson B.D., Easmon C.S., Ison C.A. Gonococcal resistance to beta-lactams and tetracycline involves mutation in loop 3 of the porin encoded at the penB locus. Antimicrob. Agents Chemother. 42:1998;2799-2803.
14. Otero L., Alcala B., Varela J.A., Miguel M.D., Vázquez J.A., Vázquez F. First isolate of a Neisseria gonorrhoeae strain associated with an ofloxacin treatment failure in Spain. Sex. Transm. Dis. 28:2001;576-578.
15. Otero L., Villar H., Vázquez J.A., Vázquez F. Neisseria gonorrhoeae resistente a quinolonas: un nuevo problema de salud pública en España. Enferm. Infecc. Microbiol. Clin. 20:2002;123-126.
16. Ruiz J., Gómez J., Navia M.M., et al. High prevalence of nalidixic acid resistant, ciprofloxacin susceptible phenotype among clinical isolates of Escherichia coli and other Enterobacteriaceae. Diagn. Microbiol. Infect. Dis. 42:2002;257-261.
17. Tavio M.M., Vila J., Ruiz J., Ruiz J., Martin-Sanchez A.M., Jiménez de Anta M.T. Mechanisms involved in the development of resistance to fluoroquinolones in Escherichia coli strains. J. Antimicrob. Chemother. 44:1999;735-742.